Preparation of solid lipid nanoparticles as drug carriers for levothyroxine sodium with in vitro drug delivery kinetic characterization

Molecular Biology Reports

Volumn 41, Issue 5, 2014, Pages 3521-3527

  Rostami, E ^a   Kashanian, S ^b   Azandaryani, A H ^a,c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b RAZI UNIVERSITY   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Kinetic release; Levothyroxine sodium; Microemulsion; Solid lipid nanoparticle

Indexed keywords

DRUG CARRIER; LIPID; NANOPARTICLE; THYROXINE;

CHEMISTRY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; KINETICS; PARTICLE SIZE; ULTRASTRUCTURE;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IN VITRO TECHNIQUES; KINETICS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; THYROXINE;

EID: 84905679573     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3216-4     Document Type: Article

References (35)

1. Alexander KS, Kothapalli MR, Dollimor D (1997) Stability of an extemporaneously formulated levothyroxine sodium syrup compounded from commercial tablets. Int J Pharm Compd 1(1):60-64
2. Ali H, El-Sayed K, Sylvester PW, Nazzal S (2010) Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by differential scanning calorimetry (DSC) and proton nuclear magnetic resonance spectroscopy (1H NMR). Colloids Surf B 77(2):286-297
3. Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59(6):478-490 (Pubitemid 47260710)
4. Arza RAK, Gonugunta CSR, Veerareddy PR (2009) Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. Am Assoc Pharm Sci 1(10):220-226
5. Barzegar-Jalali M, Adibkia K, Valizadeh H, Siahi-Shadbad MR, Nokhodchi A, Omidi Y, Mohammadi G, Hallaj-Nezhadi S, Hasan M (2008) Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci 11(1):167-177
6. Blakesley VA (2005) Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. J Am Assoc Pharm Sci 7(1):E42-E46
7. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR (2003) Duodenal administration of solid lipid nanoparticles loaded with different percentages of Tobramycin. J Pharm Sci 92(5):1085-1094 (Pubitemid 36523455)
8. Chen DB, Yang TZ, Lu WL, Zhang Q (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 49(11):1444-1447
9. Costa P, Sousa Lobo JM (2001) Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13(2):123-133 (Pubitemid 32288781)
10. Derakhshandeh K, Erfan M, Dadashzadeh S (2007) Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm 66(1):34-41 (Pubitemid 46412968)
11. Ekambaram P, Hasan-Sathali AA, Priyanka K (2012) Solid lipid nanoparticles: a review. Sci Rev Chem Commun 2(1):80-102
12. Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A (2012) Lipospheres and pro-nanolipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids 165(4):438-453
13. Freitas C, Muller RH (1998) Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. Int J Pharm 168(2):221-229 (Pubitemid 28349963)
14. Garcia-Fuentes M, Torres D, Alonso MJ (2002) Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B 27(2-3):159-168
15. Heiati H, Tawashi R, Phillips NC (1998) Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3%-azido-3%-deoxythymidinepalmitate in mice. Int J Pharm 174(4):71-80 (Pubitemid 28486991)
16. Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG (2003) Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity. Int J Pharm 254(1):83-87 (Pubitemid 36259816)
17. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S (2005) Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B 45(3-4):167-173 (Pubitemid 41415646)
18. Kamble MS, Vaidya KK, Bhosale AV, Chaudhari PD (2002) Solid lipid nanoparticles and nanostructure lipid carriers - an over view. Int J Pharm Chem Biol Sci 2(4):681-691
19. Kashanian S, Hemati Azandaryani A, Derakhshandeh K (2011) New surface modified solid lipid nanoparticles by using N-glutarylphosphatidylethanolamine as outer shell. Int J Nanomed 6(1-9):1-9
20. Kaura IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in brain targeting. J Control Release 127(2):97-109
21. Lilja JJ, Laitinen K, Neuvonen PJ (2005) Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 60(3):337-341 (Pubitemid 41224144)
22. Li XW, Lin XH, Zheng LQ, Yu L, Lv F, Zhang Q, Liu WC (2008) Effect of poly(ethylene glycol) stearate on the phase behavior of monocaprate/Tween80/ water system and characterization of poly(ethylene glycol) stearate-modified solid lipid nanoparticles. Colloids Surf A 317(1-3):352-359
23. Liu J, Gong T, Wang C, Zhong Z, Zhang Z (2007) Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 340(1-2):153-162 (Pubitemid 47044961)
24. Mehnert W, Mader K (2001) Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev 47(2-3):165-196 (Pubitemid 32324113)
25. Muller RH, Mader K, Gohla K (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50(1):161-177 (Pubitemid 30326695)
26. Parhi R, Suresh P (2010) Production of solid lipid nanoparticles-drug loading and release mechanism. J Chem Pharm Res 2(1):211-227
27. Pedersen N, Hansen S, Heydenreich AV, Kristensen HG, Poulsen HS (2006) Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm 62(2):155-162 (Pubitemid 43143267)
28. Ruktanonchai U, Bejrapha P, Sakulkhu U, Opanasopit P, Bunyapraphatsara N, Junyaprasert V, Puttipipatkhachorn S (2009) Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. Am Assoc Pharm Sci 10(1):227-234
29. Sarmento B, Martins S, Ferreira D, Souto BE (2007) Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2(4):743-749
30. Singhvi G, Singh M (2011) Review: in vitro drug release characterization. Int J Pharm Stud Res 2(1):77-84
31. Üner M, Yener G (2007) Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed 2(3):289-300 (Pubitemid 350047774)
32. Varelas CG, Dixon DG, Steiner CA (1995) Zero-order release from biphasic polymer hydrogels. J Control Release 34(3):185-192
33. Yang S, Zhu J, Lu Y, Liang B, Yang C (1999) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16(5):751-757 (Pubitemid 29227107)
34. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR (2002) Pharmacokinetics and tissue distribution of Idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharma Sci 91(5):1324-1333 (Pubitemid 34651194)
35. Zhang Q, Yie G, Li Y, Yang Q, Nagai T (2000) Studies on the cyclosporin A loaded stearic acid nanoparticles. Int J Pharm 200(2):153-159 (Pubitemid 30364902)